Sukla, Soumi and Biswas, Subhajit and Birkmann, Alexander and Lischka, Peter and Ruebsamen-Schaeff, Helga and Zimmermann, Holger and Field, Hugh J. (2010) Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant. Antiviral Research, 87 (1). pp. 67-73. ISSN 0166-3542

Full text not available from this repository.

Abstract

Point mutations in the HSV-1 UL5 (helicase) gene confer resistance to helicase-primase inhibitors (HPIs), e.g. BAY 57-1293. Such mutations normally occur at a frequency of < or =10(-6)PFU. However, individual HSV-1 laboratory strains and some clinical isolates contained resistance mutations (e.g. UL5: Lys356Asn) at 10(-4)PFU. To address the possibility that pre-existing mutants at high frequency might have an impact on therapy using HPIs, deliberate mixtures were prepared to contain the SC16 UL5: Lys356Asn mutant in SC16 wild-type in the proportion of 1/500 or 1/50PFU. Mice were infected in the neck-skin with 5x10(4)PFU/mouse of wt alone, mutant alone, or the respective mixture. The mutant could not be detected in infectious virus yields from mice inoculated with the 1/500 mixture. However, resistant mutant was recovered from some treated mice inoculated with the 1/50 mixture. All mice inoculated with mixtures remained responsive to BAY 57-1293-therapy with no increase in clinical signs compared to treatment of wt-infected mice.

Item Type:	Article
Keywords:	HSV, antivirals, helicase–primase inhibitor, antiviral resistance, murine infection model, BAY 57-1293, ref03, refdoi
Subjects:	C Biological Sciences > C540 Virology C Biological Sciences > C520 Medical and Veterinary Microbiology A Medicine and Dentistry > A300 Clinical Medicine
Divisions:	College of Sciences > Faculty of Science > School of Life Sciences
Depositing User:	Subhajit Biswas
Date Deposited:	25 Nov 2012 21:35
Last Modified:	08 May 2013 14:07
URI:	http://eprints.lincoln.ac.uk/id/eprint/6957

Actions (login required)

View Item